BIOMAT Database Logo BIOMAT Database Logo

[The first Russian trial of treating patients with acute nonlymphoblastic leukemias with novantrone combined with cytosar]. 1992

M A Volkova, and G I Kaletin

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008942 Mitoxantrone An anthracenedione-derived antineoplastic agent. Mitozantrone,CL-232325,DHAQ,Mitoxantrone Acetate,Mitoxantrone Hydrochloride,Mitroxone,NSC-279836,NSC-287836,NSC-299195,NSC-301739,NSC-301739D,Novantron,Novantrone,Onkotrone,Pralifan,Ralenova,Acetate, Mitoxantrone,CL 232325,CL232325,Hydrochloride, Mitoxantrone,NSC 279836,NSC 287836,NSC 299195,NSC 301739,NSC 301739D,NSC279836,NSC287836,NSC299195,NSC301739,NSC301739D
D010198 Pancytopenia Deficiency of all three cell elements of the blood, erythrocytes, leukocytes and platelets. Pancytopenias
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D004361 Drug Tolerance Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from DRUG RESISTANCE wherein an organism, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug. It should also be differentiated from MAXIMUM TOLERATED DOSE and NO-OBSERVED-ADVERSE-EFFECT LEVEL. Drug Tolerances,Tolerance, Drug,Tolerances, Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

M A Volkova, and G I Kaletin
["Small doses" of cytosar in the therapy of acute nonlymphoblastic leukemias].
January 1992, Terapevticheskii arkhiv,
M A Volkova, and G I Kaletin
[The current diagnosis of acute nonlymphoblastic leukemias].
January 1994, Terapevticheskii arkhiv,
M A Volkova, and G I Kaletin
Maintenance chemoimmunotherapy of nonlymphoblastic acute leukemias.
January 1982, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer,
M A Volkova, and G I Kaletin
[Megakaryocytic dysplasia in acute nonlymphoblastic leukemias].
January 1995, Terapevticheskii arkhiv,
M A Volkova, and G I Kaletin
The frequency, characteristics and outcome of infections in patients with acute nonlymphoblastic leukemias.
January 1999, Medicinski pregled,
M A Volkova, and G I Kaletin
[A trial of the use of high doses of cytosar with autologous bone marrow protection in acute leukemias].
January 1990, Terapevticheskii arkhiv,
M A Volkova, and G I Kaletin
[Acute nonlymphoblastic leukemias in children and adults].
January 1995, Klinicheskaia laboratornaia diagnostika,
M A Volkova, and G I Kaletin
[Use of the FAB-classification of acute nonlymphoblastic leukemias].
January 1985, Laboratornoe delo,
M A Volkova, and G I Kaletin
[Treating patients with acute myeloid leukemias (AML) according to the protocol of the AML-01.10 Russian multicenter randomized trial: the coordinating center's results].
January 2014, Terapevticheskii arkhiv,
M A Volkova, and G I Kaletin
[Degradation of purines in leukocytes in acute nonlymphoblastic leukemias].
January 1988, Voprosy meditsinskoi khimii,
Copied contents to your clipboard!